CONFERENCE UPDATE: ASCO 2022

Expanded biomarker analysis from faktion: fulvestrant + capivasertib vs. Fulvestrant + placebo after relapse or progression on an AI in ER+ mBC

OBSTETRICS & GYNECOLOGY ONCOLOGY
30 Jul 2022

Glossary: ABC: Advanced breast cancer; AEs: Adverse events; CDK4/6i: Cyclin dependent kinase 4/6 inhibitor; CI: Confidence interval; ECOG: Eastern Cooperation Oncology Group; DFI: Disease-free interval; ER+: Estrogen receptor positive; HER2-: Human epidermal growth factor receptor 2 negative; HR: Hazard rario; mBC: Metastatic breast cancer; OS: Overall survival; PFS: Progrssion-free survival; PS: Performance status; TTC: Time-to-chemotherapy; QD: Once daily 

Get access to our exclusive articles.
Related Articles

Biomarker analysis by NGS from SOLAR-1: Alpelisib + fulvestrant in HR+, HER2- ABC patients

Glossary: ABC: Advanced breast cancer; AI: Aromatase inhibitor; ARID1A: AT-rich interactive domain-containing protein 1A; CBR: Clinical benefit rate; CCND1: Cyclin D1; CDK4/6i: Cyclin-dependent kinase 4/6 inhibitor; CI: Confidence interval; ctDNA: Circulating tumor deoxyriboneucleic acid; ECOG: Ea
OBSTETRICS & GYNECOLOGY ONCOLOGY
30 Jul 2022